We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications
Summary
This review examines how amorphous silica nanoparticles, which are widely used in food, toothpaste, and medications, interact with the human gut microbiome. Although these particles have low acute toxicity, prolonged exposure in the gut can affect intestinal barrier function, immune responses, and the composition of gut bacteria. The findings parallel concerns about microplastics and nanoplastics, which similarly pass through the digestive system and have been shown to disrupt gut microbiota and intestinal health.
Amorphous silica nanoparticles (ASNP) are among the nanomaterials that are produced in large quantities. ASNP have been present for a long time in several fast-moving consumer products, several of which imply exposure of the gastrointestinal tract, such as toothpastes, food additives, drug excipients, and carriers. Consolidated use and experimental evidence have consistently pointed to the very low acute toxicity and limited absorption of ASNP. However, slow absorption implies prolonged exposure of the intestinal epithelium to ASNP, with documented effects on intestinal permeability and immune gut homeostasis. These effects could explain the hepatic toxicity observed after oral administration of ASNP in animals. More recently, the role of microbiota in these and other ASNP effects has attracted increasing interest in parallel with the recognition of the role of microbiota in a variety of conditions. Although evidence for nanomaterial effects on microbiota is particularly abundant for materials endowed with bactericidal activities, a growing body of recent experimental data indicates that ASNPs also modify microbiota. The implications of these effects are recounted in this contribution, along with a discussion of the more important open issues and recommendations for future research.
Sign in to start a discussion.